GNFT: מכפיל מחיר להכנסות Genfit SA

Genfit S.A. is implementing automated bioinformatics systems for the computer modeling of drugs targeting liver pathologies. The company's normalized P/S ratio allows for a correlation between the issuer's market value and actual revenues, with the 5.40 mark capturing this metric. The French expert maintains high authority within the scientific community, while monetization is based on licensing payments from pharmaceutical behemoths.

The P/S multiple assesses the market value of Genfit S.A. (GNFT) relative to its sales volume, allowing an investor to determine the asset's degree of overvaluation regardless of current earnings. By analyzing the P/S multiple, one can evaluate the effectiveness of the clinical trial and logistics outsourcing strategy, which minimizes the company's capital expenditures to concentrate resources on developing innovative therapies for liver diseases.